TYSABRI: "...It gives the treatment a 75% chance of getting the nod from the FDA: "PITY poor Kelly Martin. The Elan chief executive was only getting used to reading rosy analysts’ reports about the group’s prospects again, when Lehman Brothers spoilt the party.
Reading some of the reports coming from Dublin brokerages over the past few months, you’d have thought that the return of Tysabri to the market was as good as a done deal.

The multiple sclerosis drug was withdrawn from the market at the end of last February due to safety concerns. But, following a review of clinical data, it has been given priority status by America’s Food and Drug Administration (FDA) for further review.

Lehman believes the market may have lost the run of itself in fully pricing in a return by Tysabri to the market. It gives the treatment a 75% chance of getting the nod from the FDA. Even if it does, the broker believes some of the peak sales forecasts for the drug are just pie in the sky. ....."